openPR Logo
Press release

Primary Biliary Cholangitis Treatment Market Analysis, Company Profiles and Industrial Review Research Report Forecasting to 2026 Appraised By Global Playersv Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals

07-10-2019 12:47 PM CET | Health & Medicine

Press release from: Coherent Market Insight

Primary Biliary Cholangitis Treatment Market

Primary Biliary Cholangitis Treatment Market

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2555

Market Dynamics

Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.

Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).

Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.

Global Key Players:

Key players covered as a part of this study include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.

Detailed Segmentation:

Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
Ursodeoxycholic acid (UDCA)
Obeticholic acid (Ocaliva)

Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Primary Biliary Cholangitis Treatment Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Increasing Number Of Pipeline Studies Is Expected To Drive The Primary Biliary Cholangitis Treatment Market Growth

Increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis are expected to boost the primary biliary cholangitis treatment market size. For instance, in October 2018, CymaBay Therapeutics, Inc., initiated placebo-controlled and randomized phase 3 clinical trial for seladelpar 5-10mg. The aim of the study was to evaluate safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and to determine inadequate response or intolerance to ursodeoxycholic acid (UDCA). The study is estimated to complete in December 2021.

Moreover, in January 2017, GlaxoSmithKline (GSK) initiated phase 2 clinical trial to study the efficacy, safety, and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). GSK2330672 is a selective inhibitor of human ileal bile acid transporter (IBAT). The study is estimated to complete in April 2020.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2555

Primary Biliary Cholangitis Treatment Market- Regional Analysis

Regional segmentation of the global primary biliary cholangitis treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is anticipated to witness lucrative primary biliary cholangitis treatment market growth, owing to growing initiatives by market players to develop advance treatment options for PBC. For instance, in October 2016, TARGET PharmaSolutions, Inc., U.S.-based Company, in collaboration with Intercept Pharmaceuticals, Inc., launched its TARGET-PBC (Primary Biliary Cholangitis) platform. TARGET-PBC platform has been created to improve the understanding of real world treatment patterns in PBC.

Asia Pacific is also expected to witness significant growth in the primary biliary cholangitis treatment market. For instance, in 2017, the Japanese Biliary Association (JBA) and the Intractable Hepatobiliary Disease Study Group of Japan estimated that there were 2,000 to 3,000 patients with PBC in Japan. Also, in 2017, Japanese researchers planned to collect DNAs from Japanese PSC patients, to examine difference in genetic background between the East and the West of Japan.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis Treatment Market Analysis, Company Profiles and Industrial Review Research Report Forecasting to 2026 Appraised By Global Playersv Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals here

News-ID: 1800740 • Views:

More Releases from Coherent Market Insight

Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, Future Trends, Key Insights and Business Strategies for F. Hoffmann La-Roche Ltd., QIAGEN N.V., Becton, Dickinson and Company
Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, …
Cervical dysplasia, a condition characterized by abnormal cell changes in the cervix, is often linked to human papillomavirus (HPV) infection and smoking. It primarily affects women above the age of 30. However, it's crucial to note that cervical dysplasia is preventable, and regular cervical screening tests play a vital role in the early diagnosis of precancerous stages. This overview focuses on the key factors associated with cervical dysplasia and highlights preventive
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued at US$ 40.99 Billion by 2030, Booming Growth, Outlook, and Future Prospects | Biomedica Management Corporation, NuvOxPharma LLC
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued a …
The global High Potency Active Pharmaceutical Ingredients market size is expected to reach USD 40.99 billion by 2030, registering a CAGR of 9.9% from 2023 to 2030, according to a new report by Coherent Market Insight Inc. High potency active pharmaceutical ingredients (HPAPIs) encompass small-molecule compounds, biologics, and antibody-drug conjugates that play a crucial role in modern medicine. With their ability to precisely and selectively target diseased cells, HPAPIs have
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing industry Overview 2030 by Top Key Players | Reflexion Health, 270 Vision Ltd., CoRehab srl
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing …
The global virtual rehabilitation and telerehabilitation systems market is expected to exhibit a CAGR of 19.2% during the forecast period (2023-2030). Manufacturers are focused on development and launch of innovative rehabilitation devices, which is expected to drive the virtual rehabilitation and telerehabilitation systems market growth. For instance, in August 2019, Ekso Bionics Holdings launched its EksoNR, the next generation of its EksoGT robotic exoskeleton, developed for neurorehabilitation purposes. The device is
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Booming Growth | 10X Genomics, Abcam, Agilent
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Boom …
Single cell analysis allows for the study of individual cells within a complex biological system, providing a more detailed and comprehensive understanding of cellular behavior and function. This technology has been instrumental in advancing research in various fields, including cancer biology, immunology, and neuroscience. One of the key drivers of the single cell analysis market is the increasing demand for personalized medicine. As researchers gain a better understanding of individual cell

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
01-25-2017 | Health & Medicine
TMR
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes